Argenica Therapeutics Limited (ASX:AGN)


right-arrow Created with Sketch. -0.025 (-3.91%)
MCAP $45.00M
Last trade 15.59pm 07/12/2021 20mins delayed

Latest Announcements

17/11/2021AGNArgenica Therapeutics Limited
17/11/2021AGNArgenica Therapeutics Limited
03/11/2021 Price SensitivePSAGNArgenica Therapeutics Limited
28/10/2021 Price SensitivePSAGNArgenica Therapeutics Limited
27/10/2021AGNArgenica Therapeutics Limited
18/10/2021 Price SensitivePSAGNArgenica Therapeutics Limited
15/10/2021AGNArgenica Therapeutics Limited
14/10/2021AGNArgenica Therapeutics Limited

Company Overview

Argenica Therapeutics Limited (Argenica) is an Australia-based biotechnology company developing therapeutics to reduce brain tissue death after stroke. Argenica’s lead candidate, ARG-007, aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury. Argenica has accumulated a comprehensive body of published pre-clinical studies demonstrating efficacy of ARG-007 in multiple models of stroke and other central nervous system injury models, including stroke, traumatic brain injury and perinatal hypoxia ischaemia.

AGN in the news

Newly listed biotech Argenica Therapeutics (AGN) confirms two of its manufacturing partners…
Argenica Therapeutics (AGN) finishes its first day of trade on the ASX…

Search Previous Announcements